Clinical Trial

Fexofenadine in Patients With Active Rheumatoid Arthritis

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated July 31, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying fexofenadine mediated inhibition of TNF-α signalling
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-02-21; most recent amendment 2025-07-28.
Status change: Not Yet Recruiting → Recruiting 2022-09-19
Trial Details
NCT Number NCT05264025
Lead Sponsor October 6 University
Conditions Rheumatoid Arthritis
Enrollment 80 participants
Start Date 2022-06-01
Primary Completion 2025-12 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-31